EU Fast-Track Requests For Mozafancogene Autotemcel & Vorasidenib Signal Imminent Filings
Executive Summary
The European Medicines Agency is this week deciding whether its reviews of planned marketing applications from Rocket Pharmaceuticals and Servier merit accelerated assessment status.